GSK Australia plant to begin using blow-fill-seal technology for vaccines

GlaxoSmithKline ($GSK) has opened a new wing at its Boronia, Australia, facility as part of an effort to develop a manufacturing technique that could make the operation the first to produce a vaccine delivered by using blow-fill-seal technology. The technology forms a container, fills and then seals it to maintain a high assurance of sterility. Initially, the vaccines produced at the plant will be targeted for emerging countries. Vaccine experts from Belgium worked with the GSK team at the plant to develop the technique. GSK has invested $70 million (AU$100 million) in the unit with the Australian government pitching in a $700,000 (AU$1 million) grant. Article

Suggested Articles

Cambrex has completed installation of multiple continuous flow reactor platforms at its facility in High Point, North Carolina.

Australia’s Mayne Pharma has opened its $80 million oral solid-dose manufacturing facility in Greenville, North Carolina.

GE is launching its prefab line of drug manufacturing units that will help biopharma companies produce viral vector-based vaccines.